The inhibitory interaction of phosphodiesterase-6 (PDE6) with its c-subunit (Pc) is pivotal in vertebrate phototransduction. Here, crystal structures of a chimaeric PDE5/ PDE6 catalytic domain (PDE5/6cd) complexed with sildenafil or 3-isobutyl-1-methylxanthine and the Pc-inhibitory peptide Pc 70À87 have been determined at 2.9 and 3.0 Å , respectively. These structures show the determinants and the mechanism of the PDE6 inhibition by Pc and suggest the conformational change of Pc on transducin activation. Two variable H-and M-loops of PDE5/6cd form a distinct interface that contributes to the Pc-binding site. This allows the Pc C-terminus to fit into the opening of the catalytic pocket, blocking cGMP access to the active site. Our analysis suggests that disruption of the H-M loop interface and Pc-binding site is a molecular cause of retinal degeneration in atrd3 mice. Comparison of the two PDE5/6cd structures shows an overlap between the sildenafil and Pc 70À87 -binding sites, thereby providing critical insights into the side effects of PDE5 inhibitors on vision.
Introduction
Phosphodiesterases (PDEs) of cyclic nucleotides are major enzymes modulating cellular levels of cAMP and cGMP. Eleven class I PDE families, PDE1-11, have been identified in mammalian tissues based on their sequence homology, substrate selectivity, and regulation (Conti and Beavo, 2007; Francis et al, 2009) . The PDE6 family of enzymes serves as central effectors in the visual transduction cascade in cone and rod photoreceptors. The effector function of PDE6 is critically supported by the unique inhibitory g-subunit (Pg). In dark-adapted rods, two copies of Pg block activity of the PDE6 catalytic heterodimer PDE6AB. In cones, cone-specific Pg inhibits homodimeric PDE6C. On light stimulation, marked activation of PDE6 occurs when the activated a-subunit of the visual G-protein transducin, Ga t -GTP, binds to Pg and relieves its inhibition of PDE6 (Arshavsky et al, 2002; Lamb and Pugh, 2006; Fu and Yau, 2007) .
Each PDE6 subunit in the catalytic dimer is composed of three structural domains: two N-terminal regulatory GAF domains (GAFa and GAFb) and the conserved C-terminal PDE catalytic domain (Cote, 2004; Conti and Beavo, 2007; Francis et al, 2009) . A general map of the Pg-PDE6 interactions has been defined in biochemical studies. Two regions of Pg are primarily involved in the interaction with the PDE6 catalytic subunits, the proline-rich polycationic region (residues 24-45 of rod Pg) and the Pg C-terminus (Pg-residues 74-87) Skiba et al, 1992; Takemoto et al, 1992; Artemyev et al, 1996; Granovsky et al, 1997; Mou and Cote, 2001; Muradov et al, 2001; Guo et al, 2006) . The polycationic region of Pg binds to the PDE6 GAFa domain and importantly contributes to the overall affinity of Pg for PDE6 catalytic subunits. The C-terminus of Pg constitutes the key inhibitory domain. It interacts with the PDE6 catalytic domain and occludes the active site (Artemyev et al, 1996; Granovsky et al, 1997) . Despite the wealth of structural information developed for the PDE catalytic domains from many of the 11 families, structural data on the PDE6 catalytic domain and its interaction with Pg are lacking (Conti and Beavo, 2007; Francis et al, 2009) . The failure of functional expression of PDE6 in various systems has impeded the understanding of the structural basis of PDE6 function (Qin and Baehr, 1994; Granovsky et al, 1998; Liu et al, 2004) . Tangible progress has been achieved through characterization of chimaeric enzymes between PDE6 and the related PDE5 enzyme, which is readily attainable as recombinant protein (Granovsky et al, 1998; Artemyev, 2000, 2001a) . PDE5 and PDE6 share a common domain organization, considerable homology of the catalytic domains, specificity for cGMP relative to cAMP, and sensitivity to common catalytic-site inhibitors (Cote, 2004; Conti and Beavo, 2007; Francis et al, 2009 ). An important difference between the two PDE families is that PDE5 is not inhibited by Pg (Granovsky et al, 1998) . Only very limited PDE6 sequences seem to be allowed in bacterially expressed chimaeric PDE5/6 catalytic domains retaining enzymatic activity . Nonetheless, a replacement of the M-loop/a-helix 15 region in the bovine PDE5 catalytic domain with the corresponding sequence of bovine PDE6C yielded a fully functional chimaera C6 that was potently inhibited by Pg or the Pg C-terminal peptide, Pg 63À87 .
To study the PDE6-Pg interactions and the Pg-inhibitory mechanism by X-ray crystallography, we have generated a C6 equivalent chimaera (termed PDE5/6cd) based on the sequences of human PDE5 and PDE6. Two structures of PDE5/6cd have been solved: (1) in complex with sildenafil (Viagra) and (2) in complex with 3-isobutyl-1-methylxanthine (IBMX) and the Pg-inhibitory peptide, Pg 70À87 . These structures yield important molecular details on the interaction of the Pg C-terminus with the PDE6 catalytic subunits and the relationships between the Pg-and drug-binding sites at the catalytic pocket. Furthermore, a novel interface is revealed between the PDE H-and M-loops that is essential for Pg binding. Mutation Asn
605
Ser in PDE6B causes atypical retinal degeneration 3 (atrd3) in mice (Thaung et al, 2002; Hart et al, 2005) . The corresponding Asn residue in the PDE5/6cd structures is a critical element of the H/M-loop interface and the Pg-binding site. Our analysis suggests that impaired inhibition of PDE6 by Pg is the underlying mechanism of atrd3.
Results
Characterization of the chimaeric PDE5/6 catalytic domain, PDE5/6cd Our original Pg-sensitive PDE5/6 chimaeric catalytic domain C6 was prepared using bovine PDE5 and PDE6C sequences . All known atomic structures of the PDE5 catalytic domain have been solved using the sequence of human PDE5 (Sung et al, 2003; Card et al, 2004; Huai et al, 2004; Zhang et al, 2004; Wang et al, 2006) . Therefore, a new construct was generated based on the human PDE5 and PDE6 sequences ( Figure 1 ). This chimaeric PDE5/6 catalytic domain, PDE5/6cd, was readily expressed in Escherichia coli as a highly soluble and functional protein. Purified PDE5/6cd was analysed for enzymatic activity and the ability to interact with Pg and the inhibitory Pg peptides, Pg 63À87 and Pg 70À87 . The K m (3.6±0.3 mM) and k cat (0.55±0.04 s À1 ) for cGMP hydrolysis by PDE5/6cd are similar to those reported for the PDE5 catalytic domain (PDE5cd), but they differ from the catalytic properties of PDE6 (K m B10-50 mM, k cat B2000-4000 s
À1
)(Supplementary Figure 1) (Arshavsky et al, 2002; Cote, 2004; Wang et al, 2006) . Apparently, this is because most of the critical catalytic residues in PDE5/6cd are from PDE5. PDE5/6cd was potently and comparably inhibited by Pg (K i 1.5 ± 0.2 mM) and Pg 63À87 (K i 2.9 ± 0.3 mM), whereas the inhibition by Pg 70À87 was somewhat less potent (K i 12.1 ± 1.8 mM) (Supplementary Figure 2A) . In comparison, trypsin-activated PDE6 from bovine retina was inhibited by Pg 63À87 and Pg 70À87 with the K i of 2.2±0.3 and 3.7±0.4 mM, respectively (Supplementary Figure 2B) . This suggests that PDE5/6cd retains most of the contacts between PDE6 and the Pg C-terminus. To gain structural insights into the inhibitory interaction of the Pg C-terminus with PDE6, we attempted to obtain crystals of unliganded PDE5/6cd and its complexes with Pg, Pg 63À87 , or Pg 70À87 . In addition, crystallization screens were performed in the absence or presence of the catalytic-site inhibitors, sildenafil, and IBMX, to increase the number of potential candidates for crystal growth and explore potential drug-Pg interactions at the catalytic site. Sildenafil and IBMX inhibited cGMP hydrolysis by PDE5/6cd with K i values of 25 ± 2 nM and 8.5 ± 0.6 mM, respectively (Supplementary Figure 1B and C) . Diffracting crystals of the complexes of PDE5/6 bound with sidenafil or IBMX and Pg 70-87 were obtained and the structures were solved.
Structure of the sildenafil-bound PDE5/6cd
The crystal structure of PDE5/6cd in complex with sildenafil was solved at 2.9 Å to an R-factor of 22.3% and R-free of 27.5% (Table I ). The final model contained four molecules per asymmetric unit, and residues 536-859 of molecules A and B, residues 535-859 of molecule C and residues 537-859 of molecule D could be modelled clearly in the electron density. Electron density was clearly visible for sildenafil in each of the four molecules. The Ramachandran plot showed 99.7% of the residues to be in the most favoured or allowed regions. Molecules A and C are almost indistinguishable, and likewise, molecules B and D are nearly identical (Supplementary Table I ). Molecules A and B vary at two flexible regions defined earlier as the H-loop (residues 660-683) and M-loop (residues 788-811) (Huai et al, 2004; Wang et al, 2006) with the M-loop Figure 1 Sequence alignment of the catalytic domains of human PDE6C, PDE5A, and the chimaeric catalytic domain PDE5/6cd. The H-and M-loops are underlined with green and cyan lines, respectively. The a-helices 12 and 15 are underlined with dark green and orange lines, respectively. The PDE5cd H-loop/a-helix15 region that was replaced by the corresponding PDE6C sequence to generate PDE5/6cd is underlined with red line. Asterisk indicates PDE5/6cdAsn 661 . Alignment was generated using ClustalW.
being the most different (Supplementary Figure 3) . The omit maps for the sildenafil molecules are shown in Supplementary Figure 4A . Interestingly, sildenafil adopts a different conformation within each molecule. The conformations of sildenafil bound to PDE5/6 molecules A and C are similar, as are the conformations of sildenafil bound to molecules B and D. The methylpiperazine group of sildenafil displays the most significant conformational change (Supplementary Figure 4B) . Conformational variation of sildenafil has been recognized earlier in reported structures of sildenafil-bound PDE5cd (Wang et al, 2006) . The conformational differences in the H-and M-loop regions and sildenafil between molecules A and B are likely caused by the packing in the asymmetric unit. Within the asymmetric unit, the four H-loops are in close proximity, as are the four M-loops (Supplementary Figure 5) . However, in contrast to molecule B, the loop regions in molecule A seem to be minimally disturbed by packing (Supplementary Figure 6) . Furthermore, the B-factors for the H-and M-loops are lower in molecule A compared with molecule B (Supplementary Figure 7A and B) . Consequently, molecule A is used hereafter to describe the sildenafil-bound PDE5/6cd structure. The PDE5/6cd-sildenafil structure is compared with molecule A from the PDE5cd-sildenafil structure solved by Wang et al, as only in this structure both the H-and M-loops are fully present (Wang et al, 2006) . Except for the H-and M-loops, the overall structure of PDE5/6cd closely resembles the structure of PDE5cd in complex with sildenafil (Wang et al, 2006 ) (Supplementary Table I ). The conformation of the H-loop in the PDE5/6cd-sildenafil structure is markedly different from that in the sildenafil-bound PDE5cd. Overlay of the sildenafil-bound PDE5/6cd and PDE5cd structures shows that the H-loop moves dramatically, up to 26.2 Å , towards the M-loop in the PDE5/6cd structure even though the H-loop sequences of both structures are the same (Figure 2) . Reciprocally, the M-loop of the PDE5/6cd structure shifts up to 3.6 Å towards the bound sildenafil and H-loop. Figure 3A ). Additionally, polar residues Asn 661 and Arg 667 in the H-loop form contacts with residues Gln 789 , Glu 793 , and Gln 799 in the M-loop, respectively. In the PDE5cd-sildenafil structure, there is only one molecule that has both loops present and the B-factors for both loops of that molecule are relatively high compared with the overall structure B-factor (Wang et al, 2006) (Supplementary Figure 7C) Figure 3B ). The ability of the H-and M-loops to establish a strong interface in PDE5/6cd seems to be determined by hydrophobic interactions involving the M-loop residues Leu 792 and Val 796 . PDE5cd instead contains Arg 792 and Glu 796 . In addition to structural variations in the H-and M-loops, sildenafil assumes distinct conformations in complex with PDE5/6cd and PDE5cd. The pyrazolopyrimidinone and ethoxyphenyl groups of sildenafil occupy similar positions in the two structures. Most of the PDE5/6cd contact residues with the two groups are the same as in PDE5cd (Supplementary Figure 8) . The differences are largely confined to residues that contact the methylpiperazine group of sildenafil. Specifically, PDE5/6cd residue Met 804 (Leu 804 in (violet) is shifted to the left and the M-loop (cyan) is shifted down, bringing the two loops closer together compared with the loops of PDE5cd (wheat, PDB ID: 2H42). Grey-sildenafil (VIA) from PDE5/6cd structure; yellow-sildenafil from PDE5cd structure; light green spheres-magnesium ions (Mg); grey spheres-zinc ions (Zn).
PDE5cd) extends towards the methylpiperazine group in the PDE5/6cd structure, which results in the methylpiperazine group to straighten more and interact with Phe 823 (Ala 823 in PDE5cd) (Supplementary Figure 8) .
Structure of PDE5/6cd in complex with IBMX and Pc 70À87 The crystal structure of PDE5/6cd in complex with IBMX and Pg 70À87 was solved at 3.0 Å with non-crystallographic symmetry (NCS) restraints to an R-factor of 21.2% and R-free of 27.9% (Table I) . Each asymmetric unit contained two molecules of PDE5/6cd and two molecules of Pg 70À87 (Supplementary Figure 9A) . PDE5/6cd residues 537-859 and 535-859 of molecules A and B, respectively, were modelled clearly in the electron density. Electron density was clear for residues 71-87 of the Pg 70À87 peptide, but not for Trp 70 . Each PDE5/6cd molecule had one Pg 70À87 bound. The omit maps for Pg 70À87 are shown in Supplementary  Figure 10 . The Ramachandran plot showed all residues to be in the most favoured or allowed regions. PDE5/6cd molecules A and B are almost identical and Pg 70À87 molecules C and D are nearly indistinguishable (Supplementary Table I ). Electron density was clearly visible for IBMX in the catalytic pocket of PDE5/6cd. IBMX bound to PDE5/6cd molecules A and B adopts a similar conformation except for the orientation of the isobutyl group. The xanthine ring stacks against Phe 820 and binds to a pocket with the same residues as in the known structure of PDE5cd-IBMX (Supplementary Figure 11A and B). There were also three nonspecifically bound IBMX molecules between the asymmetric units (Supplementary Figure 11C) . The omit maps for all IBMX molecules are shown in Supplementary Figure 11C .
Excluding the H-and M-loops, the structure of PDE5/6cd in complex with IBMX/Pg 70À87 is superimposable with the published structure of PDE5cd-IBMX (Huai et al, 2004) ( Figure 4A ; Supplementary Table I ). The PDE5cd-IBMX structure is missing electron density for most of the M-loop residues and has higher B-factor values for the H-loop compared with PDE5/6cd bound with IBMX and Pg 70À87 (Supplementary Figure 12) . The PDE5/6cd H-loop adopts a different conformation than the H-loop of PDE5cd-IBMX with a divergence up to a 10.2 Å ( Figure 4A ). Remarkably, conformations of the H-and M-loops are similar in the structures of PDE5/6cd complexed with IBMX-Pg 70À87 and sildenafil ( Figure 4B ). The two structures align with an r.m.s.d of 0.49 over 323 Ca atoms (Supplementary Table I ). Both structures have good B-factor values for both of the loop regions compared with the overall structure B-factors ( Supplementary Figures 7 and 12) . The H-M-loop interface in the PDE5/6cd-IBMX-Pg 70À87 complex involves the same residues as the H-M-loop interface in the sildenafil-bound PDE5/6cd ( Figure 3C ). The side chains of the residues within the H-and M-loops are relatively close in conformation in the two PDE5/6cd structures (Supplementary Figure 13) .
Conformation of Pc 70À87 and its interface with PDE5/6cd
Residues 76-83 of Pg 70À87 bound to PDE5/6-IBMX form an a-helix and residues 84-87 form a cap near the active site ( Figure 5A ). The conformation of residues 71-74 may be affected by the crystal packing. Residues 71-74 of Pg come within close proximity with the neighbouring asymmetric unit, although there are no meaningful interactions between them (Supplementary Figure 9B and C) . The interactions between Pg 70À87 and PDE5/6cd involve residues from the H-and M-loops and a-helixes 12 and 15, and are a combination of hydrophobic, electrostatic, and Van der Waals interactions ( Figure 5B-D) . The Pg peptide blocks the active site of PDE5/6cd by completely filling the opening of the catalytic cavity ( Figure 6) Artemyev, 2000, 2001a) . However, the structure also indicates earlier unrecognized roles of the H-loop and a-helix 12 in the PDE6-Pg interface. Residue Asn 661 from the H-loop is of particular interest because it contacts the Pg backbone at Gly 85 and is a part of the H-Mloop interface that is essential for Pg binding. Furthermore, the Asn-Ser mutation of the corresponding residue Asn 605 in PDE6B causes retinal degeneration in atrd3 mice (Hart et al, 2005) . Two mutant PDE5/6cd proteins, Asn Figure 1) , but it markedly decreased the potency of PDE5/6cd inhibition by Pg (Figure 7) .
The Pg contact residues within a-helix 12 of PDE5/6cd are also involved in the intramolecular interactions essential for the integrity of the catalytic site. To examine the role of a-helix 12 in the Pg-binding interface, Ile 729 was selected for mutagenesis because it is the farthest from the catalytic pocket. Even so, the Ile 729 Ala mutation markedly reduced the activity of PDE5/6cd, precluding evaluation of the mutation effect on the inhibition by Pg.
Discussion
The inhibition of PDE6 by the small protein modulator Pg is unique among the superfamily of PDEs and is one of the central interactions in the visual transduction cascade. The atomic structure of the key inhibitory Pg fragment Pg 70À87 bound to a chimaeric PDE5/6 catalytic domain shows the molecular determinants for the selectivity of PDE6-Pg interaction and the mechanism of PDE6 inhibition by Pg. The structure also has important implications for the mechanism of PDE6 activation by transducin.
The H-M loop interface in PDE5/6cd is critical for the selective interaction with the Pc C-terminus
With the exception of two variable H-and M-loops, the core structures of PDE catalytic domains are very similar. Positions and conformations of these loops in PDE5cd are highly sensitive to the nature of ligand bound to the active site (Sung et al, 2003; Huai et al, 2004; Wang et al, 2006) . In contrast, the structures of PDE5/6cd-sildenafil and PDE5/6cd-IBMX-Pg 70À87 showed surprisingly comparable conformations of the H-and M-loops, which are stabilized by extensive inter-loop interactions. Two PDE6-specific residues from the M-loop, Leu 792 and Val 796 , are intimately involved in the H-M loop interface that distinguishes the structure of PDE5/6cd from structures of PDE5cd and other PDE catalytic domains. Thus, the H-M loop interface is an intrinsic attribute of PDE5/6cd and, in all probability, PDE6. The propensity of PDE5/6cd to form this interface might be further augmented by binding of sildenafil or IBMX/Pg 70À87 .
The structure of the PDE5/6cd-IBMX-Pg70-87 complex shows that the H-M loop interface is an essential component in the formation of the Pg-binding site. The Pg-binding The structure of the PDE-bound Pc C-terminus illuminates the PDE6 inhibition mechanism and suggests Pc conformational change on activation by transducin A recent NMR study of free Pg has concluded that it is an intrinsically disordered protein, which nonetheless contains functionally significant transient secondary and tertiary structure (Song et al, 2008) . Furthermore, the analysis suggested that residues 68-84 in free Pg are B50% helical. In the structure of the PDE5/6cd-bound Pg 70À87 , residues 76-83 form an a-helix with a cap involving residues 84-87. Therefore, the a-helix 76-83 may represent a preconfigured conformation in the free Pg that favours its binding to PDE6. The C-terminal cap 84-87 then fits snugly into the opening of the catalytic pocket and occludes access of cGMP to the active site ( Figure 6 ). The role of many of the PDE6 contact residues of Pg ( Figure 5 ) in PDE6 inhibition is consistent with previous biochemical studies (Skiba et al, 1992; Granovsky and Artemyev, 2001b) . Comparison of the PDE5/6cd-bound conformation of the Pg C-terminus with that when bound to the transition-state complex of Ga t (Slep et al, 2001 ) provides important insights into the mechanism of PDE6 activation by transducin. In the PDE5/6-and Ga t -bound states, the Pg C-terminal residues 78-87 adopt similar conformations featuring a-helices and C-terminal caps. As a consequence, the 10 C-terminal Ca atoms of Pg in the two complexes are superimposable with r.m.s.d of 0.617. However, transducin binding shortens the C-terminal a-helix of Pg from residues 76-83 to 78-83 and alters the conformation of residues 71-77. This suggests a mechanism whereby Ga t GTP interaction with the PDE6-bound Pg induces a conformational change encompassing Pg residues 71-77 and results in a hinge-like rigid-body movement of Pg-78-87 away from the PDE6 catalytic pocket. Two transducin-contact residues of Pg, Trp 70 , and Leu 76 were shown earlier to be unimportant for PDE6 inhibition but critical for PDE6 activation by transducin (Slepak et al, 1995; Tsang et al, 1998; Slep et al, 2001; Granovsky and Artemyev, 2001b) . Indeed, the structure shows that PgLeu 76 points away from PDE5/6cd and is readily accessible for binding to Ga t . Accordingly, we propose that Trp 70 and Leu 76 serve as anchors for the initial docking of Ga t GTP that leads to the activational displacement of the Pg C-terminus from PDE6. Subsequently, Ga t engages additional Pg residues, such as Phe 73 , Leu 81 , and Ile 87 , that are relieved from the interface with PDE6 (Supplementary Figure 14) .
Disruption of the PDE6-Pc interaction by a mutation causing atypical retinal degeneration in mice
Three novel mutations in the Pde6b gene were identified earlier that lead to a relatively slow onset of retinal degeneration in mice. The mutant lines were termed atrd1-atrd3 for atypical retinal degeneration (Thaung et al, 2002; Hart et al, 2005) . The atrd3 allele was originally reported to carry the missense mutation Asn 606 Ser (Hart et al, 2005) . However, our sequencing of DNA obtained from atrd3 mice indicated an Asn 605 Ser mutation, which is in agreement with the current annotation of the mutant allele at the Mouse Genome Informatics database (ID: MGI:2178316). The position corresponding to Asn 605 in mouse PDE6B is not absolutely conserved among PDEs. PDE4 contains a Ser residue at this position, which is analogous to the Asn-Ser substitution in atrd3 mice. The lack of absolute conservation and the slow progression of retinal degeneration in atrd3 mice suggest that this mutation leads to change rather than loss of PDE6 function. PDE5/6cdAsn Ser mutation moderately reduced the ability of Pg to inhibit PDE5/6cd. This effect agrees with the modelling of the Asn 661 Ser substitution into the PDE5/6cd-IBMX-Pg 70À87 structure. The side chain of Ser is able to maintain either a hydrogen bond with PgGly 85 or with the M-loop Gln 789 , but not both contacts simultaneously (Supplementary Figure 15B and C) . Analysis of the Asn 661 Ala mutation showed a much more severe impairment of the inhibition by Pg (Figure 7) . The Ala residue is predicted to loose both of the contacts with PgGly 85 and M-loop Gln 789 (Supplementary Figure 15D) . These results confirm the role of the H-M loop interface in the PDE5/6cd-Pg interaction and suggest that it is disrupted in atrd3 mice.
Interplay of the Pc C-terminus and sildenafil at the catalytic site of PDE6 PDE5 inhibitors sildenafil (Viagra) and vardenafil (Levitra) are widely used in the treatment of erectile dysfunction. However, these drugs are also potent inhibitors of PDE6 thereby causing vision impairments in some patients. The adverse effects include a blue tinge to vision, increased brightness of lights, blurry vision, and difficulty in discriminating objects (Laties and Sharlip, 2006) . Recent reports indicate that sildenafil lengthens the response time of both rods and cones significantly compared with a placebo group, thus possibly impairing the ability of the eye to adapt to light and regulate its sensitivity (Stockman et al, 2006 (Stockman et al, , 2007 . At the biochemical level, in contrast to a potent inhibition of activated PDE6, sildenafil is a poor inhibitor of holoPDE6. Consistent with the proposed competition at the catalytic site, low concentrations of sildenafil cause paradoxical activation of holoPDE6 (Zhang et al, 2005) . Potential interactions of sildenafil and Pg at the catalytic site of PDE6 are thought to be critical to understanding the mechanism of sildenafil's effects on vision (Zhang et al, 2005) . The sildenafil-and Pg 70À87 -bound structures of PDE5/6cd provide rationale for the observed effects of sildenafil on PDE6. (Figure 8 ). From the PDE5/6cd structures, the interactions of the drug and Pg with the catalytic domain seem to be mutually exclusive. Yet, we found that Pg 63À87 co-migrates with the PDE5/6cd-sildenafil complex during native gel electrophoresis (Supplementary Figure 16) . As the methylpiperazine group of sildenafil was shown to adopt multiple conformations in complexes with PDE5/6cd or PDE5cd, it may take on a conformation that allows for stacking against the PgTyr 84 . Still, the Pg interaction with PDE5/6cd is predicted to be weakened when sildenafil is bound to the catalytic pocket. Further, an alteration of the Pg C-terminus conformation caused by sildenafil may interfere with the ability of transducin to bind and activate PDE6. Our structural studies may aid in the design of selective PDE5 inhibitors lacking side effects on vision.
Materials and methods

Expression, purification, mutagenesis and characterization of PDE5/6cd
The PDE5/6cd chimaera based on sequences of human PDE5 and PDE6C is different from the bovine PDE5/PDE6 chimaera C6 at five amino acid residues. The DNA sequence corresponding to human PDE5 residues 535-786 was amplified with RT-PCR using total RNA from HEK293 cells as a template. This DNA fragment was replaced into the C6 chimaera vector using Nde I and Bgl II sites, thus allowing the changing of four out of five different residues. The remaining different amino acid residue was replaced using the QuikChange Mutagenesis protocol (Stratagene). The PDE5/6cd plasmid was transformed into BL21-codon plus competent cells (Stratagene). Expression and purification of the His6-tagged PDE5/6cd over His-bind resin (Novagen) was performed as described earlier . The eluted protein was diluted two-fold with buffer A (20 mM Tris-HCl, pH 7.5, containing 50 mM NaCl and 1 mM b-mercaptoethanol). Thrombin (final concentration 0.4 units/ml; Sigma Aldrich) and MgSO 4 (10 mM) were added to the protein followed by incubation for 16 h at 41C. The thrombin-cleaved PDE5/6cd was passed over NiSO 4 -charged His-bind resin for a second time and the flow-through fraction was collected and concentrated to a final volume of B5 ml using Amicon Ultra (30 000 MWCO; Millipore) filters. The concentrated protein was centrifuged (13 000 g, 10 min, 41C) and loaded onto Benzamidine sepharose (HiTrap Benzamidine FF; GE Healthcare) using buffer A at 1 ml/ min. Protein was eluted for 24 min with buffer A, and then for another 24 min with buffer A plus 500 mM NaCl. All fractions containing protein were combined and concentrated to a final volume of B5 ml using Amicon Ultra (30 000 MWCO) filters and loaded onto Superdex 75 sepharose (GE Healthcare) using buffer A at 1 ml/min. Fractions containing PDE5/6cd were combined and concentrated to a desired concentration (15-30 mg/ml). The purity of the protein was assessed by SDS-PAGE in 12.5% gels and Coomassie Blue staining. The PDE5/6cd protein concentration was calculated by measuring the A 280 using a NanoDrop spectrophotometer (Thermo Scientific) and e ¼ 38 234 cm/M. The monodispersity of concentrated PDE5/6cd was measured by dynamic light scattering (Protein Solutions/Wyatt Technology) at 41C after ultracentrifugation (45 000 g, 20 min, 41C). Preparations of PDE5/ 6cd with the polydispersity under 30% were stored at À801C in 10 ml aliquots for later use. Typically, 1.5 l of cell pellets yielded B5 mg of 495% pure PDE5/6cd.
The PDE5/6cd mutants Asn 661 Ser, Asn 661 Ala, and Ile 729 Ala were constructed according to the Quik Change Mutagenesis protocol (Stratagene). The sequences of all constructs were verified by automated DNA sequencing at the University of Iowa DNA Core Facility. The PDE5/6cd mutants were purified similarly to PDE5/ 6cd, except the His-tag cleavage with thrombin and chromatography over Benzamidine sepharose were omitted. Control experiments showed no differences in properties of PDE5/6cd before or after removing the His6-tag with thrombin. PDE5/6cd activity was measured using 0.5 mM [ 3 H]cGMP and 0.5-5 nM PDE5/6cd according to published protocols . Purified trypsinactivated bovine rod PDE6 was obtained as described (Artemyev et al, 1996) . Bovine PDE6 activity was measured using 5 mM [ 3 H]cGMP and 2 pM PDE6. The K m and k cat for cGMP hydrolysis and the K i values for Pg 63À87 and Pg 70À87 were determined as described . The K i values for PDE5/6cd inhibition by sildenafil and IBMX were calculated from the corresponding IC 50 values using equation (Cheng and Prusoff, 1973) and the PDE5/6cd K m value of 3.6 mM cGMP. The K m , K i , and k cat values are expressed as mean±s.e. for three separate experiments. Analysis of co-migration of unliganded, IBMX-or sildenafil-bound PDE5/6cd with Pg 63À87 using native gel electrophoresis and western blotting with antiPg 63À87 antibodies was performed as described earlier .
Crystallization and data collection
Sildenafil (Pfizer) was purified from tablets by reverse-phase chromatography using a Proteins C-4 column (Rainin), lyophilized, dissolved in H 2 O, and stored in aliquots at À801C before use. The concentration of sildenafil was determined by measuring the A 289 using a NanoDrop spectrophotometer and e ¼ 13 800 cm/M. PDE5/ 6cd and sildenafil were combined at 1:1.5 molar ratio and the protein-drug complex was ultracentrifuged at 45 000 g for 20 min at 41C. The plate-shaped crystals of PDE5/6cd bound with sildenafil were grown by hanging drop vapour diffusion at 41C against well buffer containing 100 mM Tris (pH 8.5), 200 mM MgSO 4 , 12% PEG-3350, and 2.5% ethanol. The crystals appeared after 3 weeks. Diffraction data for the PDE5/6cd-sildenafil crystal were collected at the Industrial Macromolecular Crystallography beamline at the Advanced Photon Source (Argonne National Laboratory, Chicago, IL). The crystal belonged to the spacegroup P2 1 2 1 2 1 and diffracted to a resolution of 2.9 Å .
PDE5/6cd was mixed with IBMX (Sigma Aldrich) at 1:1.5 molar ratio and the complex was ultracentrifuged at 45 000 g for 20 min at 41C. The Pg peptide Pg 70À87 was custom made by Sigma-Genosys and purified by reverse-phase HPLC. The PDE5/6cd-IBMX complex and Pg 70À87 were combined at a 1:1.25 molar ratio, incubated for 1 h on ice, and ultracentrifuged at 45 000 g for 20 min at 41C. The thin rod shaped crystals of PDE5/6cd bound with IBMX and Pg 70À87 grew within 3 days at 201C against buffer containing 100 mM HEPES (pH 8.0), 1 M sodium citrate (pH 8.0), and 2.5% ethanol. Data for . In the superimposed model of the sildenafil-bound PDE5/6cd structure and the IBMX/ Pg 70À87 -bound PDE5/6cd structure, Pg 70À87 clashes with sildenafil (VIA). The IBMX/Pg 70À87 -bound PDE5/6cd structure is shown in surface representation. PgTyr 84 is shown as sticks.
the crystal were collected remotely from the University of Iowa Protein Crystallography Facility using the 4.2.2 beamline at the Advanced Light Source (Berkeley, CA). The crystal belonged to the P2 1 2 1 2 1 spacegroup and diffracted to 3.0 Å .
Structure determination
Data for PDE5/6cd bound to sildenafil were processed using d*TREK (Pflugrath, 1999) . Phaser was used to solve the structure by molecular replacement using the PDE5cd structure bound to sildenafil (PDB entry: 2H42) as a template (Read, 2001; Wang et al, 2006) . Sildenafil and the metals were removed from the template before use in molecular replacement. Refinement was performed using the program Refmac5 of the CCP4-5.0.2 suite of programs (Collaborative Computational Project Number 4, 1994; Murshudov et al, 1997) . Coot was used for molecular visualization and model building (Emsley and Cowtan, 2004) . NCS between the four molecules was used in the refinement with tight restraints between chains A and C and between chains B and D. The metals (Mg and Zn) and Sildenafil were modelled into clearly visible electron densities. Regions of the H-and M-loops were deleted and incrementally rebuilt into the electron density. Waters were finally added to the structure using Coot, followed by manual editing. The final coordinates have been deposited to the Protein Data Bank (PDB ID: 3JWQ). Diffraction data for PDE5/6cd bound to IBMX and Pg 70À87 were also processed using d*TREK (Pflugrath, 1999) . Phaser was again used to solve the structure by molecular replacement using the PDE5/6cd structure bound with sildenafil as a template with the drug and the metals removed (Read, 2001) . As before, refinement was performed using Refmac5 and model building using Coot (Collaborative Computational Project Number 4, 1994; Murshudov et al, 1997; Emsley and Cowtan, 2004) . Tight NCS restraints were used between the two PDE5/6cd molecules in the asymmetric unit during refinement. Mg, Zn, and IBMX could easily be modelled in the electron density but the Pg 70À87 peptide had to be incrementally built in Coot, followed by refinement in Refmac5. Finally, waters were added to the structure as before. The final coordinates have been deposited to the Protein Data Bank (PDB ID: 3JWR).
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
